Resmed’s high margin and recurrent-revenue segment are the core attractions of its business. On margins, the outlook is positive Resmed’s improved update on sales costs and a proposed reduction in headcount. The impact of GLP-1 drugs on the sleep disorder device industry are overly pessimistic, but could deliver continued short term pain as the market factor in their impacts.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$38.52 |
Change
-0.330(0.85%) |
Mkt cap ! $22.41B | |||
| Open | High | Low | Value | Volume |
| $38.67 | $38.67 | $38.15 | $26.37M | 686.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 361 | $38.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $38.55 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| RMD (ASX) Chart |